Home›People›Rowan Chapman
Rowan Chapman

Rowan Chapman

Board Member at Cellanome.

DirectorPublic company
Updated Nov 10, 2026·Latest SEC filing Jul 17, 2026·Suggest an edit

About Rowan Chapman

Rowan Chapman is a board member at Cellanome.

Rowan Chapman reports to the SEC as a director or officer of 2 public companies: Natera (NTRA) and Senti Biosciences (SNTI).

Rowan Chapman first appears on SEC filings in 2019.

Experience

This experience comes from Rowan Chapman's profile and from SEC filings. For roles taken from filings, the years are when the filings name Rowan Chapman in the role, so the role may have started earlier or lasted longer.

BEVC Current
Co-Founder
2023 – Present
Stanford University Current
Adjunct Lecturer, BioEngineering
2023 – Present
Cornerstone AI Current
Board Member
2023 – Present
Cambridge Innovation Capital Current
Non Executive Director
2022 – Present
Cellanome, Inc. Current
Board Member
2021 – Present · Foster City, CA
Cellanome makes a live-cell analysis platform for biological researchers.
INITIATE Current
Co-Founder, Advisor
2020 – Present
Natera, Inc. Current
Board Member (NTRA)
2019 – Present · Public company (NTRA)
Evidation Health
Board Member
2014 – 2024
Senti Biosciences, Inc.
Chief Business Officer
2021 · Public company (SNTI)
Johnson & Johnson
Senior VP, Head of Innovation, Western North America, Australia & New Zealand
2017 – 2019
Drawbridge Health
Board Member
2015 – 2018
GE Ventures
Global Head of Healthcare Investing
2014 – 2017
GE Healthcare
Head of Precision Diagnostics, GE Healthcare Life Sciences
2012 – 2014
Personalis, Inc.
Board Member
2012
HealthTap
Board Member
2010 – 2012
Sequenta, Inc.
Board Member
2008 – 2012
Mohr Davidow Ventures
Partner
2001 – 2012
Verinata Health, Inc. (acquired by ILMN)
Board Observer
2006 – 2011
Adamas Pharmaceuticals, Inc. (ADMS)
Board Observer
2005 – 2011
Pacific Biosciences (PACB)
Board Observer
2004 – 2010
RainDance Technologies (BIORAD)
Board Observer
2004 – 2006

Key Colleagues at Startups

The people Rowan Chapman works with at each company, as listed on that company's latest Form D.

Cellanome, Inc. · Form D, Jun 22, 2026
MK
Mostafa Ronaghi
Mostafa Ronaghi
Cofounder, Executive Board Member
SP
Sandesh Patnam
Board Member
Omead Ostadan
Omead Ostadan
CEO, Board Member
Jay Flatley
Jay Flatley
Chairman

Sources

  1. SECCellanome, Inc. Form D, filed Jun 22, 2026
  2. SECForms 3, 4 and 5 filed by Rowan Chapman (SEC filer 1786240)